Accumulating data suggest that α7 nicotinic acetylcholine receptors (α7nAChRs) are an important therapeutic target for the treatment of Alzheimer’s disease (AD) and schizophrenia. This evidence concerns the gene CHRNA7 and early-onset autosomal dominant Alzheimer disease.